1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0074-7742(08)60625-x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0074-7742(08)60625-x</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
165-195
Volume
23
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Glucocorticoid Effects On Central Nervous Excitability And Synaptic Transmission
Publisher
An entity responsible for making the resource available
International Review of Neurobiology
Date
A point or period of time associated with an event in the lifecycle of the resource
1982
1905-06
Subject
The topic of the resource
Neurosciences & Neurology
Creator
An entity primarily responsible for making the resource
Hall E D
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0074-7742(08)60625-x" target="_blank" rel="noreferrer noopener">10.1016/s0074-7742(08)60625-x</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
1982
Hall E D
International review of neurobiology
Journal Article or Conference Abstract Publication
Neurosciences & Neurology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0074-7742(01)45014-8" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0074-7742(01)45014-8</a>
Pages
253–267
Volume
45
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Synaptic plasticity and secondary epileptogenesis.
Publisher
An entity responsible for making the resource available
International review of neurobiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
1905-06
Subject
The topic of the resource
Animals; Epilepsy/etiology/*physiopathology; Humans; Long-Term Potentiation/physiology; Neuronal Plasticity/*physiology; Synapses/*physiology
Creator
An entity primarily responsible for making the resource
Teyler T J; Morgan S L; Russell R N; Woodside B L
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0074-7742(01)45014-8" target="_blank" rel="noreferrer noopener">10.1016/s0074-7742(01)45014-8</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Animals
Epilepsy/etiology/*physiopathology
Humans
International review of neurobiology
Long-Term Potentiation/physiology
Morgan S L
Neuronal Plasticity/*physiology
Russell R N
Synapses/*physiology
Teyler T J
Woodside B L
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/B978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/B978-0-12-386467-3.00006-6</a>
Pages
107–125
Volume
100
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Multimodal drugs and their future for Alzheimer's and Parkinson's disease.
Publisher
An entity responsible for making the resource available
International review of neurobiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
1905-07
Subject
The topic of the resource
Alzheimer Disease/*drug therapy/*enzymology/prevention & control; Animals; Combined Modality Therapy/*methods; Forecasting; Humans; Monoamine Oxidase Inhibitors/*pharmacology/therapeutic use; Parkinson Disease/*drug therapy/*enzymology/prevention & control
Creator
An entity primarily responsible for making the resource
Van der Schyf Cornelis J; Geldenhuys Werner J
Description
An account of the resource
This chapter discusses the rationale for developing multimodal or multifunctional drugs (also called designed multiple ligands or DMLs) aimed at disease-modifying treatment strategies for the most common neurodegenerative diseases Alzheimer's and Parkinson's disease (AD and PD). Both the prevalence and incidence of AD and PD have seen consistent and dramatic increases, a disconcerting phenomenon which, ironically, has been attributed to extended life expectancy brought about by better health care globally. In spite of these statistics, the development and introduction to the clinic of new therapies proven to prevent or delay the onset of AD and PD have been disappointing. Evidence has accumulated to suggest that the etiopathology of these diseases is extremely complex, with an array of potential drug targets located within a number of deleterious biochemical pathways. Therefore, in these diseases, it is unlikely that the complex pathoetiological cascade leading to disease initiation or progression will be mitigated by any one drug acting on a single pathway or target. The pursuit of novel DMLs may offer far better outcomes. Although certainly not the only, and perhaps not even the best, approach but farthest along the drug development pipeline in the DML paradigm are drugs that combine inhibition of monoamine oxidase with associated etiological targets unique to either AD or PD. These compounds will constitute the major focus of this chapter, which will also explore radically new paradigms that seek to combine cognitive enhancers with proneurogenesis compounds.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/B978-0-12-386467-3.00006-6" target="_blank" rel="noreferrer noopener">10.1016/B978-0-12-386467-3.00006-6</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
Alzheimer Disease/*drug therapy/*enzymology/prevention & control
Animals
Combined Modality Therapy/*methods
Forecasting
Geldenhuys Werner J
Humans
International review of neurobiology
Monoamine Oxidase Inhibitors/*pharmacology/therapeutic use
Parkinson Disease/*drug therapy/*enzymology/prevention & control
Van der Schyf Cornelis J